|Day Low/High||4.25 / 4.71|
|52 Wk Low/High||3.45 / 9.38|
Five Educational Sessions Featuring Robotic Rehabilitation
The short-seller says Cyberdyne is a dog unlikely to find its way into U.S. markets.
New data from Pan-Euro Study and other clinical evidence in the field of exoskeleton therapy
The days of people confined to a wheelchair because of a stroke or a spinal cord injury may be coming to an end in the not too distant future.
Ekso Bionics Sponsors U.S.-based study of patients with chronic incomplete Spinal Cord Injury
TheStreet Quant Ratings provides fair and objective information to help you make educated investing decisions. We rate over 4,300 stocks daily and provide 5-page PDF reports for each stock. These ratings can change daily and today's changes are reflected in the email below. If you are looking to check-up on the stocks you currently own or are looking for new ideas, you can find our full database of password-protected ratings reports in our proprietary ratings screener: http://www.thestreet.com/k/qr/flat/stock-screener.html Upgrades: ABEV, ACM, ACTS, BID, CC, COH, COKE, DSCI, EGRX, FNV, NWS, SHO, SSNC Downgrades: AMBC, HHC, HLF, LXFR, ROG, TCP Initiations: APLE, CNXR, EKSO, GNL, HLTH, LIND Read on to get TheStreet Quant Ratings' detailed report:
Early findings on using Ekso GT with stroke patients to be presented by leader in motor recovery research
First robotic exoskeleton cleared for use with stroke and spinal cord injury levels to C7
Ekso Bionics to Create Flexible Exoskeleton for Soldiers; New Approach Has Potential to Revolutionize Wearable Robotics